Vifor Pharma Group said its US commercial presence has been enhanced through a pact with J&J to market Janssen’s SGLT2 inhibitor Invokana (canagliflozin) in its new indication as a treatment for diabetic kidney disease (DKD), as it will complement the Swiss group’s existing operations there.
Invokana had already been available in the US to reduce the risk of major cardiovascular events and improve glycemic control...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?